Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris

Main Article Content

L Eichenfield
L Stein Gold
N Silverberg
T Raoof
D Hooper
A Moore
M Zaiac
T Sullivan
L Kircik
E Lain
S Dhawan
T Jones
J Weiss
Z Draelos
H Ellman
T deVries
J Jankicevic
I Stuart

Keywords

acne, minocycline

Abstract

Abstract not available.

References

1. Thiboutot DM, Dreno B, Abanmi, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2S1):S1-S23.e1.

2. Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;CD002086.

3. Yentzer BA, Hick J, Reese EL, et al. Acne Vulgaris in the United States: a descriptive epidemiology. Cutis. 2010;86:94-99.

4. Zaenglein AL, PathyAL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33.

5. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80:168-177.

6. Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol. 2017;16:1022-1028.